LKT Labs

Biochemicals for Life Science Research

Belinostat

Belinostat

Product ID B1746
Cas No. 414864-00-9
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $127.00 In stock
10 mg $194.00 In stock
Bulk Quote

Quicklinks

Description

Belinostat is a histone deacetylase (HDAC) inhibitor that exhibits antiviral and anticancer chemotherapeutic activities. Belinostat is approved for use in humans in the treatment of T cell lymphoma and is currently in clinical trials as a potential treatment for other leukemias and lymphomas. In pancreatic cancer cells, belinostat induces apoptosis in an AMPK-dependent manner. In other cellular models, this compound decreases HIV release from macrophages by degrading intracellular HIV.

Product Info

Cas No.

414864-00-9
Purity

≥98%
Formula

C15H14N2O4S
Formula Wt.

318.35
IUPAC Name

(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
Synonym

PXD101
Solubility

DMSO 64 mg/mL (201.03 mM) Water Insoluble Ethanol Insoluble
Appearance

Pale yellow powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

B1746 MSDS PDF
Info Sheet

B1746 Info Sheet PDF

References

Campbell GR, Bruckman RS, Chu YL, et al. Autophagy Induction by Histone Deacetylase Inhibitors Inhibits HIV Type 1. J Biol Chem. 2015 Feb 20;290(8):5028-40. PMID: 25540204.

Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2014 Nov 17. [Epub ahead of print].
PMID: 25404094.

Kirschbaum MH, Foon KA, Frankel P, et al. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma. 2014 Oct;55(10):2301-4. PMID: 24369094.

Wang B, Wang XB, Chen LY, et al. Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis. Biochem Biophys Res Commun. 2013 Jul 19;437(1):1-6. PMID: 23743198.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • H0002

    H8 dihydrochloride

    PKA inhibitor.

    ≥98%
  • T0153

    Tanshinone I

    Diterpene found in Salvia.

    ≥95%
  • D3262

    Dipropyl Sulfide

    Organosulfide found in Allium; cholesterol synt...

    ≥99%
  • C2945

    Chlorophyllin Sodium-Copper Salt

    Semi-synthetic derivative of chlorophyll; food ...

    USP 28
  • D0032

    Daidzein

    Phytoestrogen, isoflavone found in various plan...

    ≥97%
  • G0244

    alpha-Galactosylceramide

    Synthetic glycolipid found in Agelas mauritaniu...

    ≥96%
  • F130280

    FHD-286

    BRG1/BRM ATPase inhibitor

    ≥98%
  • M9634

    Myriocin

    Atypical amino acid found in Isaria sinclairi, ...

    ≥99%, TLC
  • T6930

    Triclosan Methyl Ether

    Diarylether; bacterial ENR binder, fatty acid s...

    ≥99%
  • S8244

    Sulbactam

    β-lactamase inhibitor.

    ≥98%
  • N5769

    Norfloxacin Nicotinate

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • S0134

    Saikosaponin D

    Triterpene saponin found in Bupleurum.

    ≥98%
  • I2118

    Ifenprodil Hemitartrate

    NMDA NR1/NR2B antagonist.

    ≥98%
  • F1655

    Fenoprofen Calcium Dihydrate

    NSAID; COX-1/2 inhibitor.

    ≥97%
  • N800000

    NU-2058

    CDK1/2 inhibitor.

    ≥98%
  • M1622

    Mefenamic Acid

    NSAID; GABA-A potentiator, COX-1/2 inhibitor.

    ≥98%
  • M1752

    Men 10376

    Peptide; NK2 antagonist.

    ≥95%
  • C7997

    C-Type Natriuretic Peptide (1-22), human

    Endogenous cardiomodulatory peptide; NPR-B agon...

    ≥95%
  • V1745

    Veliparib

    PARP inhibitor.

    ≥99%
  • R5212

    RN-486

    Btk inhibitor.

    ≥98%